← All trials
NCT06535568
N/AInterventional
Trials without FDA-defined phases, including trials of devices or behavioral interventions.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 10, 2024
- Primary completion
- Oct 10, 2025
- Completion date
- Dec 20, 2026
- First posted
- Aug 2, 2024
- Last posted
- Aug 14, 2024
- Enrollment
- 416
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fondazione Ricerca e Innovazione Cardiovascolare ETSLead sponsor
- University of CantabriaCollaborator
Drugs studied
Indications studied
- Clopidogrel
- Dual Anti-Platelet Therapy
- MTOR Inhibitors
- Antineoplastic Agents
- Arterial Occlusive Diseases
- Aspirin
- Cardiovascular Diseases
- Coronary Artery Disease
- Coronary Disease
- Enzyme Inhibitors
- Heart Diseases
- Hemorrhage
- Immunosuppressive Agents
- Platelet Aggregation Inhibitors
- Vascular Diseases
- Drugs, Investigational
- Cyclooxygenase Inhibitors
- Myocardial Ischemia
- Coronary Stenosis
- Molecular Mechanisms of Pharmacological Action
- Physiological Effects of Drugs
- Protein Kinase Inhibitors
- Atherosclerosis
- Acute Coronary Syndrome
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.